Combined treatment of molnupiravir and favipiravir against SARS-CoV-2 infection: One + zero equals two?
作者信息
Eloy Philippine, Le Grand Roger, Malvy Denis, Guedj Jérémie
机构信息
INSERM CIC-EC 1425, Hôpital Bichat Claude Bernard, 75018 Paris, France.
Université Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT), Fontenay-aux-Roses & Le Kremlin-Bicêtre, Paris, France.
出版信息
EBioMedicine. 2021 Dec;74:103663. doi: 10.1016/j.ebiom.2021.103663. Epub 2021 Nov 9.
Abstract
摘要
相似文献
1
Combined treatment of molnupiravir and favipiravir against SARS-CoV-2 infection: One + zero equals two?莫努匹拉韦和法匹拉韦联合治疗新型冠状病毒感染：1加0等于2？
EBioMedicine. 2021 Dec;74:103663. doi: 10.1016/j.ebiom.2021.103663. Epub 2021 Nov 9.
2
The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model.Molnupiravir 和 Favipiravir 的联合治疗可增强 SARS-CoV-2 仓鼠感染模型中的抗病毒疗效。
EBioMedicine. 2021 Oct;72:103595. doi: 10.1016/j.ebiom.2021.103595. Epub 2021 Sep 24.
3
Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: The special case of molnupiravir.人类使用诱导致命突变的抗病毒核苷类似物药物治疗的遗传风险：莫努匹韦的特殊情况。
Environ Mol Mutagen. 2022 Jan;63(1):37-63. doi: 10.1002/em.22471.
4
Molnupiravir versus favipiravir in at-risk outpatients with COVID-19: A randomized controlled trial in Thailand.莫努匹韦与法匹拉韦治疗 COVID-19 高风险门诊患者的效果比较：泰国的一项随机对照试验。
Int J Infect Dis. 2024 Jun;143:107021. doi: 10.1016/j.ijid.2024.107021. Epub 2024 Mar 30.
5
Safety and efficacy of antivirals against SARS-CoV-2.抗新型冠状病毒（SARS-CoV-2）抗病毒药物的安全性和有效性。
BMJ. 2021 Oct 28;375:n2611. doi: 10.1136/bmj.n2611.
6
Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19.莫努匹韦的发现、研发与专利趋势：一种有前景的 COVID-19 口服治疗药物
Molecules. 2021 Sep 24;26(19):5795. doi: 10.3390/molecules26195795.
7
Efficacy of molnupiravir and interferon for the treatment of SARS-CoV-2 in golden Syrian hamster.莫努匹韦和干扰素治疗金黄地鼠 SARS-CoV-2 的疗效。
J Med Virol. 2024 Sep;96(9):e29901. doi: 10.1002/jmv.29901.
8
Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19.开发一种直接作用的、口服有效的抗病毒药物以应对大流行：莫努匹韦作为 COVID-19 潜在治疗药物的发展历程。
Curr Opin Virol. 2021 Oct;50:17-22. doi: 10.1016/j.coviro.2021.06.003. Epub 2021 Jun 18.
9
Molnupiravir: coding for catastrophe.莫努匹拉韦：引发灾难的编码。
Nat Struct Mol Biol. 2021 Sep;28(9):706-708. doi: 10.1038/s41594-021-00657-8.
10
Molnupiravir: A new candidate for COVID-19 treatment.莫努匹韦：COVID-19 治疗的新候选药物。
Pharmacol Res Perspect. 2022 Feb;10(1):e00909. doi: 10.1002/prp2.909.
引用本文的文献
1
Genetic consequences of effective and suboptimal dosing with mutagenic drugs in a hamster model of SARS-CoV-2 infection.在新冠病毒（SARS-CoV-2）感染的仓鼠模型中，使用致突变药物进行有效和次优剂量给药的遗传后果。
Virus Evol. 2024 Jan 4;10(1):veae001. doi: 10.1093/ve/veae001. eCollection 2024.
2
Favipiravir Analogues as Inhibitors of SARS-CoV-2 RNA-Dependent RNA Polymerase, Combined Quantum Chemical Modeling, Quantitative Structure-Property Relationship, and Molecular Docking Study.法匹拉韦类似物作为 SARS-CoV-2 RNA 依赖的 RNA 聚合酶抑制剂：组合量子化学建模、定量构效关系和分子对接研究。
Molecules. 2024 Jan 16;29(2):441. doi: 10.3390/molecules29020441.
3
[Not Available].[无可用内容]
Acta Pharm Sin B. 2024 Jan;14(1):87-109. doi: 10.1016/j.apsb.2023.08.004. Epub 2023 Aug 9.
4
Elucidating the Role of Noncovalent Interactions in Favipiravir, a Drug Active against Various Human RNA Viruses; a H-N NQDR/Periodic DFT/QTAIM/RDS/3D Hirshfeld Surfaces Combined Study.阐明非共价相互作用在法匹拉韦中的作用，法匹拉韦是一种针对多种人类 RNA 病毒有效的药物；H-N NQDR/周期性密度泛函理论/键级拓扑分析/离域密度响应/三维 Hirshfeld 表面综合研究。
Molecules. 2023 Apr 7;28(8):3308. doi: 10.3390/molecules28083308.
5
Identification of Z-Tyr-Ala-CHN, a Cathepsin L Inhibitor with Broad-Spectrum Cell-Specific Activity against Coronaviruses, including SARS-CoV-2.Z-Tyr-Ala-CHN的鉴定，一种组织蛋白酶L抑制剂，对包括SARS-CoV-2在内的冠状病毒具有广谱细胞特异性活性。
Microorganisms. 2023 Mar 10;11(3):717. doi: 10.3390/microorganisms11030717.
6
Evaluation of molnupiravir (EIDD-2801) efficacy against SARS-CoV-2 in the rhesus macaque model.评估莫那比拉韦（EIDD-2801）在恒河猴模型中抗 SARS-CoV-2 的疗效。
Antiviral Res. 2023 Jan;209:105492. doi: 10.1016/j.antiviral.2022.105492. Epub 2022 Dec 16.
7
Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.奈玛特韦片/利托那韦片组合包装用于 COVID-19 的预防和治疗。
Cochrane Database Syst Rev. 2022 Sep 20;9(9):CD015395. doi: 10.1002/14651858.CD015395.pub2.
8
COVID-19: Some unresolved issues.新型冠状病毒肺炎（COVID-19）：一些未解决的问题。
Rev Esp Quimioter. 2022 Oct;35(5):421-434. doi: 10.37201/req/028.2022. Epub 2022 Apr 21.
9
Molnupiravir: A lethal mutagenic drug against rapidly mutating severe acute respiratory syndrome coronavirus 2-A narrative review.莫努匹韦：一种针对快速突变的严重急性呼吸综合征冠状病毒 2 的致命诱变药物——叙事性综述。
J Med Virol. 2022 Jul;94(7):3006-3016. doi: 10.1002/jmv.27730. Epub 2022 Apr 2.
Zotero 插件